Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy

Discrimination between Circulating Endothelial Cells and Blood Cell Populations with Overlapping Phenotype Reveals Distinct Regulation and Predictive Potential in Cancer Therapy

(2015) Patrick Starlinger et al.   NEOPLASIA

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

(2011) Eric Tartour et al.   CANCER AND METASTASIS REVIEWS

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

(2010) Andrew H. Ko et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

(2009) F.-C. Bidard et al.   ANNALS OF ONCOLOGY

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel

(2009) Makoto Kawaishi et al.   Journal of Thoracic Oncology

CXCL8/IL-8 and CXCL12/SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer

(2008) Yoichi Matsuo et al.   INTERNATIONAL JOURNAL OF CANCER